Loading...
NPI 1780059717 · Albuquerque, NM · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Southwest Labs LLC is a clinical medical laboratory provider located in Albuquerque, New Mexico. This profile covers 23 Medicare and 143 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Southwest Labs LLC |
| Address | 4261 Balloon Park Rd Ne |
| City | Albuquerque |
| State | NM |
| ZIP | 87109 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 2, 2015 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $41.5M |
| Medicare | $1.1M |
Payer mix is heavily skewed toward Medicaid: reported lifetime Medicaid revenue is $41.5M versus $1.1M in Medicare, so Medicaid represents the overwhelming majority of this provider’s publicly reported volume. The precomputed concentration metrics also show the top 3 Medicaid codes account for 67.2% of Medicaid revenue while the top 3 Medicare codes account for 84.6% of Medicare revenue, indicating that a small set of services drives most income in each payer stream.
Service-line profile points to a high-volume clinical reference laboratory that combines large-scale definitive drug testing with broad infectious-agent nucleic acid testing. Drug-testing CPT/HCPCS such as G0483, G0482 and G0481 dominate Medicare and Medicaid lists (G0483 alone generates $688.5K Medicare and $14.7M Medicaid), while NAAT codes such as 87798, 87801 and a range of amplified-probe codes (e.g., 87481, 87641, 87653) appear throughout the top code sets, consistent with a lab that offers both forensic/toxicology panels and molecular infectious-disease testing.
Medicare revenue concentration is extreme at the code level: the provider’s top 3 Medicare codes account for 84.6% of Medicare revenue, with G0483 contributing $688.5K (62.2% of Medicare revenue), G0482 $180K (16.2%), and 87798 $69K (6.2%). Despite these shares, the Medicare code-level descriptors label the provider’s volumes as "typical, unremarkable" for these codes, suggesting the provider is a solid contributor nationally but not an extreme national outlier on Medicare for the listed tests.
On Medicaid the provider is a statewide leader for multiple codes: G0483 is ranked #1 of 8 in-state and labeled "notably above typical state volume for this code," 87798 is ranked #1 of 23 and labeled an "extreme outlier, far above typical state volume for this code," and 80307 is listed as an "extreme outlier" as well. Those top Medicaid generators—G0483 (76.8K claims, $14.7M), 87798 (19.9K claims, $8.9M) and 80307 (67.9K claims, $3.7M)—are responsible for the 67.2% concentration, indicating dominant market share in New Mexico for both definitive drug testing and several high-volume screening assays.
National competitive standing on Medicare is mixed: G0483 ranks #33 of 1063 (97th percentile) and G0482 ranks #81 of 1618 (95th percentile), signaling above-average national placement on key drug-testing codes, yet the provided qualitative labels describe these as "typical, unremarkable volume for this code." This combination suggests the provider is a recognized national contributor on specialty drug panels while Medicare volumes remain within the range of many other labs rather than uniquely extreme.
Operational throughput is implied to be high by the raw claim counts on Medicaid for several assays: G0483 has 76.8K claims, 80307 has 67.9K claims, and 87798 has 19.9K claims. Those counts, combined with large Medicaid payments (e.g., $14.7M and $8.9M), are consistent with a centralized, high-throughput lab model that processes large specimen volumes for state Medicaid populations and payer networks.
Several Medicaid codes show state-level outlier status across a broad range of molecular targets (e.g., 87653, 87641, 87581, 87529, 87486 all rank at or near #1 in-state with labels like "exactly above typical" or "extreme outlier" where noted), indicating the lab’s footprint extends beyond drug testing into a wide array of molecular infectious-disease diagnostics. This breadth of high-volume NAAT activity reinforces that the provider functions as a major in-state reference lab for both routine and specialized molecular assays.
The provider has an established operating history with NPI enumeration date 2015-12-02 (~11 years ago), which aligns with the pattern of extensive Medicaid contracting and scaled service lines visible in the billing data. That tenure, combined with concentrated code-level revenues and in-state leadership on multiple codes, positions the entity as a durable market participant in New Mexico’s lab services marketplace.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
23 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,850 | $240 | $688.5K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 920 | $200 | $180K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 2,030 | $30 | $69K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 680 | $70 | $46.9K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 200 | $150 | $31.1K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 310 | $60 | $19K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 210 | $70 | $15.3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 100 | $110 | $10.8K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 200 | $30 | $6.7K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 150 | $30 | $5.2K |
Showing 1–10 of 23
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 23 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
143 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 76,790 | $190 | $14.7M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 19,860 | $450 | $8.9M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 67,940 | $60 | $3.7M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 14,200 | $150 | $2.1M |
| 87632 | The lab analyst performs a test to identify a respiratory virus using an amplified nucleic acid probe technique. He may also use the multiplex reverse transcription technique. The provider does this… | 6,320 | $240 | $1.5M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 12,440 | $120 | $1.5M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 17,910 | $70 | $1.2M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 15,980 | $60 | $879K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 20,860 | $30 | $709.1K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,640 | $130 | $704.6K |
Showing 1–10 of 143
How this provider's Medicaid billing volume and revenue compare to other New Mexico providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Mexico median
143 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 10 | 690 | $190 | $2M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 3 | 80 | 3,340 | $60 | $595K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 1 | 10 | 16,330 | $30 | $541.1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 4 | 40 | 880 | $80 | $527.4K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 1 | 20 | 790 | $240 | $493.1K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 10 | 530 | $150 | $415.5K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 16 | 20 | 250 | $410 | $330.3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 50 | 530 | $90 | $323.8K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 57 | 100 | 2,650 | $10 | $265.6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 4 | 20 | 1,590 | $30 | $247K |
Showing 1–10 of 143
Other providers in the same ZIP code as Southwest Labs LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.